

Table 4. Quality of life, dyspnoea, cough and fatigue in the study group before and after 12 months of pirfenidone treatment

	Before treatment (n = 52)	After treatment (n = 52)	p
SF-36			
SF-36 PCS	42.33 ± 8.73	48.45 ± 13.84	0.004
SF-36 MCS	44.60 ± 11.85	53.82 ± 17.32	0.003
PF	39.85 ± 9.08	42.03 ± 13.75	0.12
RP	44.73 ± 23.66	74.07 ± 50.54	0.001
BP	43.84 ± 12.77	29.94 ± 18.53	0.001
GH	39.91 ± 10.08	46.24 ± 11.86	0.001
VT	45.20 ± 10.77	40.19 ± 9.95	0.01
SF	40.74 ± 9.6	40.24 ± 7.64	0.60
RE	47.76 ± 31.23	96.87 ± 66.95	0.0001
MH	42.96 ± 10.09	39.98 ± 8.52	0.015
SGRQ - Total	46.69 ± 20.62	47.09 ± 20.27	0.68
Symptoms	52.04 ± 21.24	54.24 ± 21.37	0.48
Activity	55.63 ± 23.31	57.58 ± 23.81	0.65
Impact	39.54 ± 23.95	37.56 ± 21.87	0.65
BDI Total	7.22 ± 2.45	7.34 ± 2.50	0.49
Functional Impairment	2.56 ± 1.07	2.58 ± 1.08	0.50
Magnitude of Task	2.58 ± 0.91	2.67 ± 0.84	0.56
Magnitude of Effort	2.32 ± 0.91	2.26 ± 0.94	0.72
LCQ	14.47 ± 3.74	15.24 ± 3.61	0.59
Fatigue Assessment Scale	24.02 ± 7.06	23.98 ± 7.84	0.59

PCS – Physical Cumulative Score, MCS – Mental Cumulative Score, PF – Physical Function, RP

– Role-Physical, BP – Bodily Pain, GH – General Health, VT – Vitality, SF – Social Functioning,

RE – Role-Emotional, MH – Mental Health, SGRQ – St. George’s Respiratory Questionnaire,

BDI – Baseline Dyspnoea Index, LCQ – Leicester Cough Questionnaire